Compare VMI & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VMI | ABVX |
|---|---|---|
| Founded | 1946 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 9.2B |
| IPO Year | N/A | N/A |
| Metric | VMI | ABVX |
|---|---|---|
| Price | $467.35 | $124.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $462.33 | $130.09 |
| AVG Volume (30 Days) | 116.9K | ★ 984.0K |
| Earning Date | 02-17-2026 | 03-23-2026 |
| Dividend Yield | ★ 0.57% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 11.66 | N/A |
| Revenue | ★ $4,103,136,000.00 | $6,231,374.00 |
| Revenue This Year | $1.86 | $6.80 |
| Revenue Next Year | $4.12 | N/A |
| P/E Ratio | $40.99 | ★ N/A |
| Revenue Growth | ★ 1.23 | N/A |
| 52 Week Low | $250.07 | $4.77 |
| 52 Week High | $487.58 | $148.83 |
| Indicator | VMI | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 64.08 | 57.35 |
| Support Level | $469.40 | $115.93 |
| Resistance Level | $487.58 | $116.72 |
| Average True Range (ATR) | 12.27 | 5.06 |
| MACD | 1.28 | 1.14 |
| Stochastic Oscillator | 60.49 | 94.60 |
Valmont Industries Inc, along with its subsidiaries, operates as a manufacturer of products and services for infrastructure and agriculture markets. Its reportable segments are Infrastructure and Agriculture. The company generates maximum revenue from the Infrastructure segment, which includes the manufacturing and distribution of products and solutions to serve the infrastructure markets of utility, solar, lighting and transportation, and telecommunications, along with coatings services to protect metal products. The Agriculture segment provides irrigation equipment components, including aftermarket parts and tubular products, and technology solutions for precision agriculture. Geographically, it derives key revenue from the United States, followed by Australia, Brazil, and other regions.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.